Pro-Dex earnings beat by $0.26, revenue topped estimates

Pro-Dex (PDEX) reported Q1 EPS of $0.92, beating estimates by $0.26, with revenue of $20.6M, exceeding expectations. The stock is up 5.17% in 3 months and 101.11% in 12 months. InvestingPro rates its financial health as 'great performance'.

Original reporting
Published Oct 29, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PDEX
Bullish
high confidence
Mentioned
$PDEX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PDEXBullishMed
01

Why it matters

The immediate trading focus is whether the EPS and revenue beat changes expectations for subsequent quarters, but the article does not include forward guidance.

02

Market read

A reported EPS and revenue beat is a direct catalyst for repricing the stock versus analyst expectations.

03

What to watch

The article omits guidance, balance-sheet/cash-flow details, and segment performance, which often determine whether the beat translates into sustained upside.

Relevance 8/10Novelty 8/10Timing: after-hours/next-session reaction to the just-reported Q1 results

Background

The piece is an Investing.com earnings writeup for Pro-Dex’s first-quarter results versus analyst consensus.

Company-level read

Ticker impact

$PDEXBullishHigh confidence
Context

Pro-Dex reported Q1 EPS of $0.92, above the $0.66 estimate, and revenue of $20.6M versus $19.6M consensus.

Expected impact

Likely upward bias as the market digests the earnings beat versus consensus.

Evidence & confidence

The article provides the quarter’s EPS and revenue versus analyst estimates, which is the core driver for post-earnings repricing.

Market effects

Limited sector read-through because the article is single-company earnings with no guidance or industry datapoints.

No clear regional spillover beyond small-cap NASDAQ sentiment.

No global macro or cross-border linkage mentioned.

Counterpoint

A headline beat may not sustain if margins, cash flow, or forward guidance (not provided here) disappoint.

Key entities

  • Pro-Dex

    NASDAQ-listed company reporting Q1 EPS and revenue versus consensus estimates.

Related articles

$PDEXMed

PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS

PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS IRVINE, CA, October 29, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2027 fi

$PDEXMed

PRO DEX INC (PDEX): Quarter Ended June 30, 2026

PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 FOURTH QUARTER AND FULL-YEAR RESULTS IRVINE, CA, September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for i

$INKTHigh

MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H…

MiNK Therapeutics, Inc. (INKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies November 11, 2026 & Patients with serious unmet medical need access agenT-797 through phy